Quest Diagnostics upgraded by Leerink Partners with a new price target
$DGX
Medical Specialities
Health Care
Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $195.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $185.00 | Buy → Neutral | Citigroup |
| 1/6/2025 | $169.00 → $174.00 | Market Perform → Outperform | Leerink Partners |
| 12/17/2024 | $145.00 → $172.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $175.00 → $185.00 | Buy | Jefferies |
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird |
| 8/28/2024 | $165.00 | In-line | Evercore ISI |
| 7/10/2024 | $145.00 → $165.00 | Neutral → Buy | Citigroup |
11-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
S-3ASR - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q
SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings. Under terms of the agreement, Quest will develop and validate a laboratory-developed blood test based on circulating protein biomarkers associated with high risk for one or more cancers, including colorectal,
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care SECAUCUS, N.J., May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-initiated testing platform from Quest Diagnostics (NYSE:DGX), one of the nation's leading providers of diagnostic information services, today revealed the results of its second "Know Your Health" survey, conducted online by The Harris Poll among nearly 2,100 U.S. adults. Findings revealed that most America
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00
Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00
Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously